Biomarin Pharmaceutical INC 8-K filings

BioMarin Pharmaceutical Inc. announced a 20% year-over-year increase in total revenue for the second quarter of 2024 and raised its full-year guidance.

BioMarin Pharmaceutical Inc. successfully held its 2024 Annual Meeting of Stockholders, electing all nominated directors and ratifying KPMG LLP as its independent auditor.

BioMarin will reduce its global workforce by approximately 170 employees after a strategic review of its research and development programs.

BioMarin announced record financial results for the first quarter of 2024, highlighted by a 9% year-over-year revenue increase and a 70% jump in GAAP diluted earnings per share, driven by strong VOXZOGO sales and strategic R&D focus.

BioMarin Pharmaceutical Inc. has reached a settlement in two stockholder derivative lawsuits, agreeing to implement corporate governance reforms and pay up to $1.25 million in legal fees.

BioMarin announced record financial results for 2023, driven by strong sales of VOXZOGO, and provided a positive financial outlook for 2024.

BioMarin Pharmaceutical Inc. announced that its Executive Vice President and Chief Commercial Officer, Jeffrey Ajer, will step down effective July 1, 2024.